ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -197.98M | -171.30M | -80.04M | -48.02M | -15.65M |
| Total Depreciation and Amortization | 1.48M | 1.37M | 979.00K | 609.00K | 348.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 22.41M | 19.07M | 16.90M | 13.88M | 9.28M |
| Change in Net Operating Assets | -988.00K | -20.00M | -23.22M | -19.27M | -14.46M |
| Cash from Operations | -175.07M | -170.87M | -85.38M | -52.80M | -20.48M |
| Capital Expenditure | -248.00K | -339.00K | -641.00K | -584.00K | -571.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 55.74M | 57.11M | -68.47M | -6.72M | -67.95M |
| Cash from Investing | 55.50M | 56.77M | -69.11M | -7.31M | -68.52M |
| Total Debt Issued | 96.26M | 96.26M | 97.75M | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.02M | 5.68M | 5.43M | 5.64M | 3.48M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.76M | 2.66M | 71.20M | 69.38M | 69.38M |
| Cash from Financing | 104.03M | 104.60M | 174.38M | 75.02M | 72.87M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -15.54M | -9.50M | 19.90M | 14.91M | -16.14M |